

Daily evidence digest

21 January 2022

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Rapid COVID tests, Omicron and therapeutic monoclonal antibodies, breakthrough infections, Omicron symptoms

Peer reviewed journals featured:

- A systematic review on rapid point-of-care tests for SARS-CoV-2 infections in children [here](#)
- A narrative review on Omicron and therapeutic monoclonal antibodies [here](#)
- A randomised controlled trial of boosters after Johnson & Johnson (Janssen) vaccine priming [here](#)
- Observational studies on:
 - Rapid diagnostic testing for SARS-CoV-2 [here](#)
 - mRNA boosters against Omicron [here](#)
 - Clinical outcomes in hospitalised COVID-19 children and adolescents in six sub-Saharan African countries [here](#) and associated editorial [here](#)
- An editorial on the need to update the official list of COVID-19 symptoms [here](#)
- Commentary on
 - Milder disease with the Omicron variant [here](#)
 - A health system strategy to safely provide surgical care during COVID-19 in the US [here](#)

Letters and correspondence discussed:

- Breakthrough infections with Omicron despite mRNA vaccine booster dose [here](#)
- Effectiveness of mRNA vaccines in Qatar [here](#)

Pre-peer review articles featured:

- COVID-19 breakthrough infection after inactivated vaccination [here](#)
- Omicron-associated changes in SARS-COV-2 symptoms in the UK [here](#)
- The value of vaccine booster doses to mitigate the global impact of the Omicron variant [here](#)
- Effectiveness of mRNA vaccines against Omicron among US Veterans [here](#)

Guidance and reports

- The World Health Organization published:
 - Rapid qualitative research to increase COVID-19 vaccination uptake [here](#)
 - A meeting report on managing the COVID-19 pandemic and preparing primary health care to meet future health needs [here](#)
- The Therapeutic Goods Administration (TGA) issued provisional approval to molnupiravir (LAGEVRIO) and nirmatrelvir + ritonavir (PAXLOVID) for use in oral COVID-19 treatment [here](#)

News and blogs

- Lateral flow tests in children fail minimum performance standards [here](#)
- COVID-19 vaccine makers chase variant-ready vaccines [here](#)
- How does Omicron spread so fast? [here](#)
- NEJM audio interview on crushing the COVID-19 curve [here](#)

[Click here](#) to subscribe to the daily evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on [COVID-19 transmission](#), SARS-CoV-2 [vaccines](#), and [variants](#) of concern, [post-acute sequelae of COVID-19 \(PASC\)](#), [surgery and COVID-19](#), [rapid testing](#) and [risk mitigation strategies](#).